Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess all aspects of cognition, today announced it is part of a successful consortium of 46 industry and
Cambridge Cognition plc (LON:COG) CEO Dr Matthew Stork joins DirectorsTalk to discuss a contract win for three phase II studies with a new pharmaceutical client. Matthew provides us with some background
Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has today announced that the Company has won a contract for three phase II studies
Cambridge Cognition Holdings plc (LON:COG, which develops and markets neuroscience technology to assess brain health, is pleased to announce a conditional Placing and Subscription to raise gross proceeds of £1.4
Cambridge Cognition (LON:COG), which develops and markets digital solutions to assess brain health, has announced the launch of an improved electronic clinical outcomes assessment (eCOA) platform that has already attracted
Following a consultation with the U.S. Food and Drug Administration, Biogen (Nasdaq:BIIB) and Eisai, Co., Ltd (Tokyo, Japan) have announced plans to pursue regulatory approval for aducanumab, which would be
Cambridge Cognition Holdings PLC (LON:COG), which develops and markets digital solutions to assess brain health, today announced its unaudited Interim Results for the six months ended 30 June 2019. As announced in
Cambridge Cognition Holdings PLC (LON:COG), which develops and markets digital solutions to assess brain health, today announced a trading update ahead of the release of the Company’s interim results for
Cambridge Cognition Holdings PLC (LON:COG), which delivers digital solutions for optimising cognitive assessment, today announced its expansion into the Chinese market with the Company’s Cambridge Neuropsychological Test Automated Battery computerised
Matthew Stork, Chief Executive Officer at Cambridge Cognition said: “We are delighted to have received an order from a leading pharmaceutical company to trial the NeuroVocalix™ platform. We are also
© 2025 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
